ANR Anatara Lifesciences Ltd
Healthcare · Biotechnology
· website
$0.01
52wk 0.01 – 0.02
Overall
43.1
Value
73.8
Growth
0.0
Health
100.0
Quality
0.0
Momentum
26.6
Dividend
—
Price
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | -10.0% |
| 3 months | -10.0% |
| 6 months | 0.0% |
| 1 year | -40.0% |
| 3 years | -65.8% |
Risk
| Volatility (1y ann.) | 75.4% |
| Beta vs ASX 200 | 0.40 |
| Sharpe (1y) | -0.36 |
| VaR 95% (1-day) | -9.1% |
| Max drawdown (1y) | -43.8% |
| Off 1-year high | -43.8% |
Technicals
| RSI(14) | 100 OB |
| vs 50DMA | -3.4% |
| vs 200DMA | -11.8% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
73.8
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
49
Price / Sales
12
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
26.6
6-month return vs ASX 200
46
Price vs 200-day average
11
Price vs 50-day average
33
Position in 52-week range
11
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$2.85M
P/E (trailing)
—
P/E (forward)
0.45
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
0.69
EV / EBITDA
-2.54
Price / Book
4.50
ROE
-149.6%
Operating margin
-299.8%
Net margin
-293.1%
Total cash
$470,917
Total debt
$0
Current ratio
7.58
Debt / Equity
—
Free cash flow
$19,690
Avg volume
54,699
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.01
- Free cash flow—
- Net debt—